NIFTY 50 23344.75 ▲ (0.61%)
NIFTY NEXT 50 65106.15 ▲ (0.08%)
NIFTY 100 24048.8 ▲ (0.51%)
NIFTY MIDCAP 100 55106.2 ▲ (0.91%)
NIFTY SMALLCAP 100 17864.65 ▲ (1.09%)
NIFTY SMALLCAP 250 16841.4 ▲ (0.84%)
NIFTY MIDCAP SELECT 12356.5 ▲ (0.87%)
NIFTY TOTAL MARKET 12304.6 ▲ (0.6%)
NIFTY BANK 49350.8 ▲ (1.67%)
SENSEX 77073.44 ▲ (0.59%)
BSE BANKEX 56036.23 ▲ (2.03%)

Strides Pharma Science : Q1 2024 Financial Quarterly Report : YoY Sales Up 16.71 %, QoQ Down 10.18 %

July 29, 2024July 29, 2024| adminadmin| 0 Comments| 6:00 pm
Image is loading
Categories:

Share the post "Strides Pharma Science : Q1 2024 Financial Quarterly Report : YoY Sales Up 16.71 %, QoQ Down 10.18 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • The presented financial data is Standalone to provide a comprehensive overview of the company performance.
  • Sales over the Year and quarter: The company experienced a substantial growth of 16.71 % in the past year, decrease in net sales/revenue by -10.18 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 1.57 %. Marginal decrease of -59.98% in other income during this quarter.
  • Profit over the Year and quarter: Challenges in sustaining profitability for Strides Pharma Science Limited. Profit dropped by -51.02 % Year to Year, Strides Pharma Science Limited’s profitability dropped by -92.7 % Quarter to Quarter.
  • EPS over the Year and quarter: EPS declined by -51.69 % Year to Year. EPS decreased by -92.64 % in previous quarter. Analysis needed for shareholder value.

The comprehensive analytics outlining the performance and outlook of Strides Pharma Science Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 475.322 Cr Rs. 617.632 Cr Rs. 554.751 Cr -10.18 % + 16.71 %
Expenses Rs. 419.75 Cr Rs. 526.84 Cr Rs. 493.72 Cr -6.29 % + 17.62 %
Operating Profit Rs. 55.57 Cr Rs. 90.79 Cr Rs. 61.03 Cr -32.78 % + 9.83 %
OPM % 11.69 % 14.7 % 11 % -3.7 % -0.69 %
Other Income Rs. 11.647 Cr Rs. 29.56 Cr Rs. 11.83 Cr -59.98 % + 1.57 %
Interest Rs. 36.63 Cr Rs. 46.77 Cr Rs. 46.88 Cr + 0.24 % + 27.98 %
Depreciation Rs. 21.46 Cr Rs. 20.81 Cr Rs. 20.32 Cr -2.35 % -5.31 %
Profit before tax Rs. 9.13 Cr Rs. 52.77 Cr Rs. 5.66 Cr -89.27 % -38.01 %
Tax % 12.35 % 1.68 % 30.81 % + 29.13 % + 18.46 %
Net Profit Rs. 8 Cr Rs. 53.66 Cr Rs. 3.92 Cr -92.69 % -51 %
EPS in Rs Rs. 0.89 Rs. 5.83 Rs. 0.43 -92.62 % -51.69 %


Today, we’re looking at Strides Pharma Science Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 16.71 %. However, it did see a marginal slip of -10.18 % from the previous quarter. Expenses decreased slightly by -6.29 % quarter-on-quarter, aligning with the annual rise of 17.62 %. Operating profit, while up 9.83 % compared to last year, faced a quarter-on-quarter dip of -32.78 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -0.69 %, but a shrinkage of -3.7 % sequentially. Other income fell by -59.98 % compared to the last quarter, despite an annual growth of 1.57 %. Interest expenses surged remarkably by 0.24 % from the previous quarter, yet the year-over-year increase remains at a moderate 27.98 %. Depreciation costs fell by -2.35 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -5.31 %. Profit before tax declined annually by -38.01 % but saw a reduction from the preceding quarter by -89.27 %.
Tax expenses as a percentage of profits increased slightly by 18.46 % compared to last year, with a more notable quarter-on-quarter increase of 29.13 %. Net profit fell by -51 % year-on-year but witnessed a -92.69 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -51.69 % but a quarterly fall of -92.62 %. In summary, Strides Pharma Science Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 475.322 Cr Rs. 617.632 Cr Rs. 554.751 Cr -10.18 % + 16.71 %
Expenses Rs. 419.75 Cr Rs. 526.84 Cr Rs. 493.72 Cr -6.29 % + 17.62 %
Operating Profit Rs. 55.57 Cr Rs. 90.79 Cr Rs. 61.03 Cr -32.78 % + 9.83 %
Net Profit Rs. 8 Cr Rs. 53.66 Cr Rs. 3.92 Cr -92.69 % -51 %
EPS in Rs Rs. 0.89 Rs. 5.83 Rs. 0.43 -92.62 % -51.69 %


In reviewing Strides Pharma Science Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 16.71 % year-on-year growth, although there was a slight dip of -10.18 % from the previous quarter. Expenses rose by 17.62 % compared to the previous year, with a decrease of -6.29 % quarter-on-quarter. Operating Profit surged by 9.83 % annually, and saw a -32.78 % decrease from the last quarter.
Net Profit showed yearly decrease of -51 %, and experienced a -92.69 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -51.69 % annually, however dipped by -92.62 % compared to the last quarter. In essence, while Strides Pharma Science Limited faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Escorts Kubota “]

Related Post